Combination Cancer Therapy

Expert physician-scientists and clinicians review those combinations of novel target agents classic chemotherapies that hold the most promise for the future of medical oncology, and detail their optimal sequence, pharmacokinetic interactions, and interaction with downstream cellular signals. The combinations run the gamut of targeted therapies against cell surface receptors (EGF-R and HER2), the cell cycle (the CDKs), signal transduction events (PKC and NF-kB), apoptosis (bcl-2), as well as focused therapies in ovarian cancer, hematologic diseases, and breast cancer. The authors emphasize novel translational approaches that are rapidly moving from the laboratory bench top to the patient's bedside for the future treatments in cancer therapy.

Targeting of the EGFR As a Modulator of Cancer Chemotherapy. - Cyclin-Dependent Kinase Inhibitors in Combination Chemotherapy. - Development of Protein Kinase C and Cyclin-Dependent Kinase Inhibitors As Potentiators of Cytotoxic Drug Action in Leukemia. - Carboxyamidotriazole, an Inhibitor of Nonvoltage-Operated Calcium Entry. - Targeted ? -Particle Therapy. - Pharmacological Modulation of Fluoropyrimidines. - Development of Inhibitors of HER2 With Taxanes. - Targeting NF-? B to Increase the Activity of Cisplatin in Solid Tumors. - Combinations of Chemotherapy and G3139, an Antisense Bcl-2 Oligonucleotide. - Use of Animal Models to Evaluate Signal Transduction Inhibitors As Modulators of Cytotoxic Therapy.